Clinical Trial Update: Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pazopanib hydrochloride for stage IV or recurrent nasopharyngeal carcinoma has completed. Results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoepithelioma of the Nasopharynx
• Nasopharyngeal Carcinoma
• Squamous Cell Carcinoma of the Nasopharynx

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Nasopharynx | Phase 2 | Status: COMPLETED | Results posted: 2015-12-17